Volume 22, Issue 2 (3-2018)                   ibj 2018, 22(2): 76-77 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Salimi M. Future of Triple Negative Breast Cancer: Can Immunotherapy Treat This Deadly Subtype of Breast Cancer?. ibj. 2018; 22 (2) :76-77
URL: http://ibj.pasteur.ac.ir/article-1-2240-en.html
Abstract:  

Triple negative breast cancer (TNBC): challenges and solutions via the immune cells

TNBC is one of the most complicated types of breast cancer to treat. It is generally diagnosed based on the absence of three receptors: estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) and is thus defined as a triple negative. TNBC is often more aggressive with lower survival rates than other forms of breast cancer; however, the outlook depends on the stage of diagnosis. This type of breast cancer cannot attract potent anti-cancer and hormone drugs due to the lack of surface proteins, so patients diagnosed with the disease have to rely almost exclusively on chemotherapy. In recent years, immunotherapy has gained attention, as a developing option, to treat a subset of cancers... 

Type of Study: Study Break | Subject: Related Fields

Add your comments about this article : Your username or Email:
CAPTCHA

© 2020 All Rights Reserved | Iranian Biomedical Journal

Designed & Developed by : Yektaweb